Last edition
News about "Kerendia"
Bayer Secures Japanese Approval for Finerenone
Bayer has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Finerenone (Kerendia), a non-steroidal, selective mineralocorticoid receptor antagonist, for the treatment of adult patients with chronic heart failure with mildly reduced or preserved Left Ventricular Ejection Fraction (LVEF).
Kerendia | 23/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members